Get started
Author

Yen-Lin Chu

Observed institution: Epic Sciences (United States)
ORCID: 0000-0003-3182-8831
Observed ORCID: 0000-0003-3182-8831
OpenAlex ID: A5065426990
Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer
2022 · Anthony V. Serritella, Daniel Shevrin, et al. · Clinical Cancer Research · 57
Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer
2020 · Heather J. Chalfin, Tiziano Pramparo, et al. · Clinical Cancer Research · 41
PDF
Supplementary Figure from Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer
2023 · Anthony V. Serritella, Daniel Shevrin, et al.
PDF
Data from Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer
2023 · Anthony V. Serritella, Daniel Shevrin, et al.
Data from Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer
2023 · Anthony V. Serritella, Daniel Shevrin, et al.
Supplementary Figure from Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer
2023 · Anthony V. Serritella, Daniel Shevrin, et al.
Supplementary Figure from Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer
2023 · Anthony V. Serritella, Daniel Shevrin, et al.
PDF
Supplementary Figure from Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer
2023 · Anthony V. Serritella, Daniel Shevrin, et al.
Supplementary Figure from Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer
2023 · Anthony V. Serritella, Daniel Shevrin, et al.
Supplementary Figure from Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer
2023 · Anthony V. Serritella, Daniel Shevrin, et al.
PDF
Supplementary Data from Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer
2023 · Heather J. Chalfin, Tiziano Pramparo, et al.
Supplementary Data from Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer
2023 · Heather J. Chalfin, Tiziano Pramparo, et al.
PDF
Data from Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer
2023 · Heather J. Chalfin, Tiziano Pramparo, et al.
Data from Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer
2023 · Heather J. Chalfin, Tiziano Pramparo, et al.
Works count: 14
Citation count: 98
H-index: 2
I10-index: 2
Year
Topic
Type